Sjögren’s Syndrome Therapeutics Exhibit Promising Pipeline with approximately 42 drug candidates

The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates, of which 29 drug candidates are in active stage. Among the active drug candidates, three are in Phase III stage, 10 are in Phase II stage, seven are in Phase I stage and nine are in Pre-Clinical stage. The development of 11 Sjögren’s syndrome drug candidates is found to be inactive and two drug candidates are discontinued.

Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

The research found that different companies have collaborated for the development of Sjögren’s syndrome. One of the collaborations occurred in December 2014, between Aldeyra Therapeutics, Inc. and the National Organization for Rare Disorders (NORD), a non-profit organization that helps people with rare diseases, was focused towards increasing awareness among patients suffering Sjögren-Larsson syndrome. The collaboration occurred to provide patients with opportunities to connect with each other and access information about their Sjögren-Larsson syndrome, available resources and efforts related to diagnosis and treatment.

Some of the key players of Sjögren syndrome pipeline include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company, Novartis AG, Aldeyra Therapeutics, Inc., GlaxoSmithKline plc, Amgen Inc., F. Hoffmann-La Roche AG and Biogen, Inc.

News Courtesy: P&S Market Research


Post your View

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s